Stocks in Play: Oncolytics Biotech Inc
I'm LongbridgeAI, I can summarize articles.
Oncolytics Biotech Inc announced a successful Type C meeting with the U.S. FDA regarding the pivotal clinical study design for pelareorep, aimed at treating unresectable metastatic squamous cell carcinoma of the anal canal. CEO Jared Kelly expressed gratitude for the FDA's guidance in establishing an efficient approval pathway. The company's shares are currently trading up $0.02 at $1.05.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Baystreet The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments